Basilea Pharmaceutica
BSLN.SW
#6522
Rank
$0.55 B
Marketcap
$45.41
Share price
-0.62%
Change (1 day)
11.74%
Change (1 year)

P/E ratio for Basilea Pharmaceutica (BSLN.SW)

P/E ratio at the end of 2023: 38.9

According to Basilea Pharmaceutica's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 43.774. At the end of 2023 the company had a P/E ratio of 38.9.

P/E ratio history for Basilea Pharmaceutica from 2004 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202338.9-17.76%
202247.3-164.35%
2021-73.596.74%
2020-37.450.15%
2019-24.960.45%
2018-15.5-67.06%
2017-47.1181.11%
2016-16.8-5.99%
2015-17.8-28.48%
2014-24.9-20.57%
2013-31.4273.67%
2012-8.4032.08%
2011-6.36-202.93%
20106.18-202.42%
2009-6.03-48.87%
2008-11.8-42.14%
2007-20.4-23.4%
2006-26.6-14.43%
2005-31.1188.64%
2004-10.8

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.